At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 440 enrolled

Drug / intervention

Oxymetazoline HCL Cream 1.0%drug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02095158

NCT02095158Phase 3Completed

Compare CT.gov

A Long-term Safety and Efficacy Study of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea

Allergan·interventional·Posted Mar 24, 2014·Updated Nov 18, 2019

In Brief

A Phase 3 clinical trial evaluating Oxymetazoline HCL Cream 1.0% for Erythema and Rosacea. Completed, enrolled 440 participants across 1 site.

Detailed Summary

This study will evaluate the long-term safety and efficacy of oxymetazoline hydrogen chloride (HCL) Cream 1.0% (AGN-199201) in patients with persistent erythema associated with rosacea.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsErythema, Rosacea

CountriesUnited States

Collaborators--

Timeline

Phase 3CompletedFinished

2014201520162017201820192020202120222023202420252026

First PostedMar 2014

Enrollment StartApr 2014

Primary CompletionAug 2015

Study CompletionSep 2015

TodayJul 2026

First PostedMar 24, 2014

Enrollment StartApr 1, 2014

Primary CompletionAug 1, 2015

Study CompletionSep 1, 2015

TodayJul 2, 2026

Enrollment to primary: 1.3 yearsPosted 12.3 years ago

Interventions

Oxymetazoline HCL Cream 1.0%drug

Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.